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ABSTRACT: The WNT signaling system governs critical processes during
embryonic development and tissue homeostasis, and its dysfunction can
lead to cancer. Details concerning selectivity and differences in relative
binding affinities of 19 mammalian WNTs to the cysteine-rich domain
(CRD) of their receptorsthe ten mammalian Frizzleds (FZDs)remain
unclear. Here, we used eGFP-tagged mouse WNT-3A for a systematic
analysis of WNT interaction with every human FZD paralogue in
HEK293A cells. Employing HiBiT-tagged full-length FZDs, we studied
eGFP-WNT-3A binding kinetics, saturation binding, and competition
binding with commercially available WNTs in live HEK293A cells using a
NanoBiT/BRET-based assay. Further, we generated receptor chimeras to
dissect the contribution of the transmembrane core to WNT-CRD binding.
Our data pinpoint distinct WNT-FZD selectivity and shed light on the
complex WNT-FZD binding mechanism. The methodological development described herein reveals yet unappreciated details of the
complexity of WNT signaling and WNT-FZD interactions, providing further details with respect to WNT-FZD selectivity.
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G protein-coupled receptor (GPCR)
The ten mammalian Frizzleds (FZD1−10) are G protein-coupled receptors (GPCRs) and formtogether with
Smoothened (SMO)the class F of GPCRs.1,2 The 19
different WNT lipoglycoproteins are the main macromolecular
ligands of FZDs, interacting with the extracellular cysteine-rich
domain (CRD) of the receptor. WNT-FZD signaling
orchestrates multiple processes during embryonic develop-
ment, stem cell regulation, and adult tissue homeostasis.2
Additionally, aberrant WNT signaling is implicated in
tumorigenesis and other pathologies.3,4 Whereas recent
advances have resulted in a better understanding of the
underlying mechanisms controlling WNT-induced FZD
activation and signal initiation, the relative binding affinities
and ligand−receptor selectivity remain largely unknown.5−13
The quantitative assessment of WNT binding has been limited
by the strong lipophilicity of WNTs, which makes their
purification challenging and necessitates detergents and serum
for solubilization and stabilization of WNTs, respectively.14,15
Nevertheless, WNT-FZD interactions were studied using
biochemical and biophysical assays as well as through the
use of in silico calculations.16−22 These studies generally
reported WNT-FZD binding affinities in the range of 1−100
nM, which is reasonable when considering the known affinities
of proteinaceous ligands to other GPCRs.23,24 Nevertheless, it
remains unclear how these values translate into the
physiological reality, since the local concentration of WNTs
at the receptors in vivo remains unknown and is likely to be
highly context-dependent.25 Until recently, the assessment of
ligand binding was based on WNT binding to the CRD rather
than the full-length FZD, or the reported assays were not
performed in live cells. However, progress has been made with
the use of FRET- and cpGFP-based biosensors to demonstrate
WNT-induced FZD conformational dynamics and receptor
activation,7,12,26 where WNT binding to a full-length receptor
was reflected by an outward movement of the transmembrane
domain TM6. Furthermore, the generation of a functional
eGFP-tagged WNT-3A provided for the first time a bio-
logically relevant FZD ligand that could be used as a probe in
quantitative binding assays in real-time using living cells.27,28
Here, using live cell analysis of transiently transfected
HEK293A cells overexpressing HiBiT-tagged FZDs, we
provide a comparative assessment of binding affinities of
eGFP-WNT-3A to all human FZD paralogues using kinetic
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and saturation binding formats. Furthermore, using a
competition binding assay, we have assessed binding affinities
of unlabeled, commercially available WNT proteins to FZD4.
Finally, we have also explored the contribution of the FZD
transmembrane core for the binding of WNTs to the primary
FZD-CRD binding site.29 Compared with the previously
described BRET-based assay for Nluc-FZD4 and Nluc-FZD6,
28
we have used a nanoluciferase complementation-based BRET
binding approach here, termed NanoBiT/BRET. In this BRET
assay format, the fluorescent WNT-3A binds FZDs that are N-
terminally tagged with the 11-amino-acid HiBiT peptide. The
addition of the complementary LgBiT to the system allows
rapid and high-affinity association to the HiBiT peptide,
forming a stable NanoBiT moiety with a luciferase activity.
This setup allows targeted analysis of cell surface receptors due
to the cell impermeability of LgBiT, thereby providing a
system with less intracellular background luminescence. This
method is a modification of a well-established NanoBRET
binding assay to study ligand−receptor association,30 and has
been lately employed to study ligand binding to Class A
GPCRs and receptor tyrosine kinases.31−34 Our results
demonstrate that eGFP-WNT-3A interacts with full-length
human FZDs transiently overexpressed in live HEK293A cells
in a paralogue selective manner. This concept was expanded to
unlabeled WNTs in competition binding experiments suggest-
ing a complex WNT-FZD selectivity profile. The binding data
based on full-length FZDs, FZD-CD86, and FZD-FZD
chimeras underline the complexity of the WNT-FZD
interaction and suggest that the core regions of FZDs may
contribute to receptor selectivity.
■ RESULTS AND DISCUSSION
eGFP-WNT-3A/FZD Binding Kinetics. In order to
establish a nanoluciferase complementation-dependent Nano-
BiT/BRET binding assay format to study all human FZD
paralogues, we generated constructs for all 10 receptors
carrying an N-terminal HiBiT tag (Figure S1A,B). Upon
transient overexpression in HEK293A cells, all receptor
constructs were detected at the cell surface, albeit with varying
cell surface expression levels (Figure S1C). Additionally,
HiBiT-tagged FZD1, FZD2, FZD4, FZD5, FZD7, FZD8, and
FZD10 mediated WNT-3A-induced β-catenin-dependent sig-
nals as assessed by the TOPFlash reporter assay performed in
HEK293T cells devoid of endogenous FZDs (ΔFZD1−10
Figure 1. eGFP-WNT-3A binding kinetics. A. The scheme depicts the experimental setup of the NanoBiT/BRET analysis of association kinetics
between the HiBiT-tagged FZD and the eGFP-WNT-3A. Created with BioRender.com. B. Association kinetics of the eGFP-WNT-3A to human
HiBiT-FZDs were determined by the detection of NanoBiT/BRET in transiently overexpressing living HEK293A cells over time. BRET was
sampled once per 90 s for 240 min. Data points are presented as means ± SEM from n = 3 individual experiments, fitting a two or more hot ligand
concentrations kinetics model. Experiments were performed with eGFP-WNT-3A batch 1.
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HEK293T cells, Figure S1D25). In contrast, FZD3, FZD6, and
FZD9 could not transduce WNT-3A-induced activation of this
pathway, similar to what has been reported previously, yet with
differing results for FZD9.
28,35−38 Having verified the sequence
and functionality of the HiBiT-tagged FZD constructs,
HEK293A cells transiently overexpressing these FZDs were
used in kinetic binding experiments. For these experiments,
cells were first incubated with the complementary LgBiT
protein and the luciferase substrate vivazine, and after 1 h,
eGFP-WNT-3A was added to final concentrations of 2.1, 4.2,
or 8.3 nM, and BRET readings were taken over a 4 h period at
37 °C (Figure 1A). The concentrations used for eGFP-WNT-
3A were dictated by the maximal concentration that could be
obtained for the eGFP-WNT-3A preparations and the assay
format. We detected a saturable net BRET ratio indicative of
eGFP-WNT-3A specific binding to HiBiT-tagged FZD1, FZD2,
FZD4, FZD5, FZD7, and FZD10, with Kd values varying from
2.3 to 29.9 nM (Figure 1B, Table 1). In line with the
TOPFlash data, no concentration-dependent increase in
receptor−ligand BRET was detected for FZD3 and FZD9.
Interestingly, FZD8, which maintained a strong WNT-3A-
induced TOPFlash activity, and to a lesser extent FZD6,
displayed very low but detectable binding that could be fitted
to association curves over time (Figure S2A).
eGFP-WNT-3A/FZD Binding Affinity at Equilibrium.
To define saturation binding affinity of eGFP-WNT-3A, we
incubated human HiBiT-FZDs with a full concentration range
(16.7 pM to 16.7 nM) of eGFP-WNT-3A for 240 min at 37 °C
(Figure 2A). The net BRET ratio representing ligand−receptor
binding increased in a clear, concentration-dependent manner
Table 1. Kinetic and Saturation Binding Parameters of eGFP-WNT-3A Binding to All 10 Human HiBiT-Tagged FZD
Paraloguesa
FZD1 FZD2 FZD3 FZD4 FZD5 FZD6 FZD7 FZD8 FZD9 FZD10
Kinetic binding Kd
(nM) ± SEM
29.9 ± 1.5 5.4 ± 0.1 n.d. 9.4 ± 0.5 2.3 ± 0.2 10.2 ± 3.7 2.8 ± 0.2 17.8 ± 4.4 n.d. 4.3 ± 0.3
Saturation binding Kd
(nM) ± SEM
36.7 ± 12.7 48.6 ± 8.2 n.d. 17.7 ± 7.2 14.9 ± 7.6 6.5 ± 5.7 24.9 ± 9.9 4.9 ± 3.1 n.d. 21.3 ± 9.0
aKd values are based on data from n = 3−4 individual experiments (shown in Figures 1B and 2B) and shown as a best-fit value ± SEM; n.d. = not
determined.
Figure 2. eGFP-WNT-3A saturation binding. A. The scheme depicts the experimental setup of NanoBiT/BRET analysis of equilibrium binding
between the HiBiT-tagged FZD and the eGFP-WNT-3A. Created with BioRender.com. B. Saturation binding of the eGFP-WNT-3A to human
HiBiT-FZDs was determined by the detection of NanoBiT/BRET in transiently overexpressing living HEK293A cells following 240 min
incubation. Data points are presented as means ± SEM from n = 4 individual experiments, fitting a one-site specific model models. Experiments
were performed with eGFP-WNT-3A batch 1.
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for FZD1, FZD2, FZD4, FZD5, FZD7, and FZD10. Unfortu-
nately, using transient overexpression of HiBiT-FZDs in
HEK293A cells and the eGFP-WNT-3A with a limited
maximal concentration in the conditioned medium, binding
curves did not reach maximal asymptotic values but only came
to near-saturable levels (Figure 2B). Again, detection of
binding of eGFP-Wnt-3A to FZD6 and FZD8 was only
marginally above background levels, as the net BRET values
were low (Figure S2B). Similar to the kinetic binding assays,
no quantifiable eGFP-WNT-3A binding was detected for FZD3
or FZD9. The affinities of eGFP-WNT-3A/FZD interactions
were determined from linear regression curves showing near-
saturable binding,39 and the Kd values are shown in Table 1.
The reported saturation binding affinity values range from 4.9
to 48.6 nM, and they are in good agreement with the Kd values
determined with kinetic binding for FZD1, FZD4, and FZD6.
The degree of agreement is, however, only fair for FZD5,
FZD8, and FZD10 and relatively poor for FZD2 and FZD7.
Taken together, these kinetic and saturation binding data are in
line with our previous results using fluorescence microscopy
analysis, where no eGFP-WNT-3A association could be
observed with C-terminally mCherry-tagged FZD6, and only
a very weak association with FZD8 and FZD9 (FZD3 was not
used).28 Although this fluorescence imaging-based method
Figure 3. Competition binding between eGFP-WNT-3A and untagged WNTs at FZD4. A. The scheme depicts the experimental setup of
NanoBiT/BRET analysis of competition binding between the eGFP-WNT-3A and commercially available untagged WNT-3A, WNT-5A, WNT-
5B, WNT-10B, WNT-11, and WNT-16B. Created with BioRender.com. B. FZD4 binding of eGFP-WNT-3A at 0.4 nM in the presence of
increasing concentrations of the untagged WNTs was determined by the detection of NanoBiT/BRET in transiently overexpressing living
HEK293A cells following 240 min incubation. Data points are presented as means ± SEM from n = 3−6 individual experiments, fitting a three- or
four-parameter model. Upper dashed line indicates the BRET ratio of eGFP-WNT-3A-only treated cells; lower dashed line indicates the BRET
ratio of ligand-untreated cells (BRET donor only). Experiments were performed with eGFP-WNT-3A batch 2.
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could provide an estimate of the relative ability of eGFP-WNT-
3A to associate with different FZDs, accurate quantification of
the binding affinities was not possible. Also, in that study,
ΔFZD1−10 HEK293GFP‑free cells overexpressing FZD8-mCherry
(but not FZD6-mCherry), showed very faint binding of eGFP-
WNT-3A, and this is also in agreement with the HiBiT-tagged
system used here, which can detect very low level, but specific,
binding to FZD8 (Figure S2). This is in agreement with a
recent report claiming that ligand−receptor interaction using
the HiBiT-tagged system allows detection of very weak
interactions.32 Furthermore, in the case of FZD6, there are
differences in reports of its ability to bind or respond to WNT-
3A. Biochemical experiments failed to detect any association
between WNT-3A and FZD6-CRD-IgG,
16 and no eGFP-
WNT-3A/Nluc-FZD6 interaction was detected in our previous
NanoBRET study.28 However, it should be noted that,
compared with the HiBiT-tagged systems, binding analyses
with Nluc-tagged receptors can display reduced sensitivity for
detection of weak interactions, as recently discussed.32 On the
other hand, recombinant human WNT-3A induced a
conformational change in FZD6
12 and affected the mobility
of the receptor in the cell membrane as assessed by
fluorescence recovery after photobleaching assay.40 Finally,
the findings with respect to FZD8 are particularly intriguing,
given the existing structural information on the WNT-3A-
FZD8 CRD complex.
41 It is currently unclear why such
discrepancies exist for these two FZD paralogues.
In order to directly compare NanoBiT/BRET and Nano-
BRET binding assay formats, we used Nluc-FZD4 and HiBiT-
FZD4 constructs for saturation binding (Figure S3A−C).
NanoBiT/BRET experiments were performed in two different
experimental paradigms, where LgBiT protein was added
either directly after (setup 1, used throughout this study Figure
S3B and Figure 2A) or for 10 min before (setup 2, Figure
S3C) the 4 h incubation with eGFP-WNT-3A. This allowed us
to test for any potential steric hindrance of WNT binding to
FZD caused by the presence or complementation of
nanoluciferase. In these comparisons, although the differences
in Kd values were apparent, they did not reach statistical
significance (Nluc-FZD4 Kd (nM) ± SEM = 7.6 ± 3.6; HiBiT-
FZD4 setup 1 Kd (nM) ± SEM = 11.9 ± 3.6; HiBiT-FZD4
setup 2 Kd ± SEM (nM) = 20.4 ± 7.6). Furthermore, eGFP-
WNT-3A binding to Nluc-FZD4 (Figure S3A) resulted in
lower maximal BRET (BRETmax) compared to either of the
two HiBiT-FZD4 binding setups (Figure S3B,C) at similar
luminescence levels (Nluc-FZD4 BRETmax ± SEM = 0.026 ±
0.006 vs HiBiT-FZD4 setup 1 BRETmax ± SEM = 0.049 ±
0.005, P = 0.0484; vs HiBiT-FZD4 setup 2 BRETmax ± SEM =
0.049 ± 0.004, P = 0.0349). This suggests that intracellular
luminescence originating from receptors that are not accessible
for the ligand reduces the assay’s dynamic range (see Figure
S3D for expression analysis). In support of our choice to
change from NanoBRET to the NanoBiT/BRET experimental
setup, a recent study has shown that affinity measurements
obtained from NanoBRET binding assays were generally less
consistent in comparison with NanoBiT/BRET analyses.32
eGFP-WNT-3A Competition Binding with Untagged
WNTs at FZD4. With the aim to understand the competitive
nature of eGFP-WNT-3A binding to FZD, we combined
eGFP-WNT-3A with increasing concentrations of several
commercially available and purified untagged WNT proteins:
WNT-3A, WNT-5A, WNT-5B, WNT-10B, WNT-11, and
WNT-16B. Again, we have used HiBiT-FZD4 as our model
receptor. In this assay setup, HEK293A cells transiently
overexpressing HiBiT-FZD4 were preincubated with the
untagged WNTs for 30 min before addition of eGPF-WNT-
3A to a final concentration of 0.4 nM. Cells were then
incubated for a further 4 h to allow a competitive equilibrium
to be reached before addition of LgBiT and subsequent BRET
measurement (Figure 3A). The results of these experiments
are shown in Figure 3B and summarized in the Table 2, and
show that the untagged WNTs competitively displaced eGFP-
WNT-3A from FZD4 with different affinities and capacities.
Interestingly, WNT-10B and WNT-11 had the highest
affinities, but they showed moderate BRET signal decrease as
indicated by remaining residual BRET. Intriguingly, WNT-3A
presented higher binding affinity (lower Kd) but caused a lower
reduction of BRET than WNT-5A and WNT-5B. WNT-16B
did not compete with eGFP-WNT-3A in this FZD4-based
assay. These results are in fair agreement with the recently
published potencies and efficacies of WNTs in eliciting
conformational changes in FZD4-cpGFP biosensor except for
WNT-5B.12 Nevertheless, a similar rank order of affinities was
obtained for WNT-3A, WNT-5A, and WNT-5B in binding to
the isolated FZD4 CRD.
17 Obviously, the insights into the
mechanism of WNT−WNT competition for the primary
binding site at FZDs remain obscure. We can only speculate
that the process of functional ligand binding is more complex
than for small-molecule ligands and other GPCRs. Along these
lines, FZD oligomers associate or dissociate upon ligand
addition,42−44 adding to the complexity of ligand binding
analysis.45 Additionally, FZD coreceptors and various regu-
lators could alter WNT interactions with FZD in HEK293
cells.25
Binding of eGFP-WNT-3A to FZD Chimeras. WNTs
directly engage the CRD through protein−protein and
protein−lipid interactions.41,46 However, it remains unclear
whether non-CRD domains of FZDs contribute to WNT-FZD
interaction.20 It has been hypothesized that the CRD simply
serves the purpose of binding WNTs in order to bring them in
close proximity with the receptor for additional binding/
activation mechanisms.47 Indeed, the long and flexible nature
of the linker connecting the CRD of FZDs to TM1 would tend
to support such a hypothesis.48 The role of the FZD
transmembrane domains in ligand binding, complex formation,
receptor conformational changes, and signal transduction has
Table 2. Binding Properties of Various FZD Ligands in Competition with eGFP-WNT-3A Binding (0.4 nM) to HiBiT-FZD4
a
WNT-3A WNT-5A WNT-5B WNT-10B WNT-11
WNT-
16B
Competition binding pKi ± SEM 7.26 ± 0.35 7.08 ± 0.21 6.93 ± 0.25 7.87 ± 0.55 8.90 ± 0.66 n.d.
ΔBRET ± SEM −0.002 ± 0.001 −0.004 ± 0.0002 −0.004 ± 0.0002 −0.001 ± 0.0003 −0.001 ± 0.0004 n.d.
0.4 nM eGFP- WNT-3A binding displaced
(%)
40.8 78.4 78.3 34.5 58.4 n.d.
aData are based on n = 3−6 individual experiments presented in Figure 3B. pKi values are presented as a best-fit value ± SEM; n.d. = not
determined.
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been a subject of debate.5,8,9,49−52 Here, we seek to obtain a
more mechanistic insight into the contribution of the
transmembrane core to eGFP-WNT-3A binding. To this
end, we generated two chimeric proteins fusing the N-terminal
domain (NTD; CRD + linker) of one FZD with an unrelated
CD86 single transmembrane domain spanning protein (Figure
4A). Specifically, we generated FZD4-CD86 and FZD8-CD86
chimeric proteins (Figure S4A). In this manner, we aimed to
study the effect of a FZD core on eGFP-WNT-3A binding to
the CRD. We validated the chimeras with regard to proper
membrane trafficking upon transient overexpression in
HEK293A cells and detected no difference in surface
Figure 4. eGFP-WNT-3A binding to FZD-CD86 chimeras. A. The cartoon representations of the FZD-CD86 fusion proteins used in this study.
eGFP-WNT-3A binding at equilibrium was assessed as depicted in Figure 2A. Created with BioRender.com. B. Cell surface expression of HiBiT-
tagged FZD-CD86 chimeras as measured by NanoBiT luminescence (from the experiments summarized in Figure 2B and parts C−D). Data are
presented as means ± SEM from n = 3−4 individual experiments. Expression data of FZD4, FZD8, and pcDNA are also depicted in SI Figure 1C. C.
Saturation binding of eGFP-WNT-3A at FZD4-CD86 and FZD4 (data also present in Figure 2B) was determined by the detection of NanoBiT/
BRET in transiently overexpressing living HEK293A cells following 240 min incubation. Data points are presented as means ± SEM from n = 3−4
individual experiments. eGFP-WNT-3A batch 1 was used in these experiments. D. Saturation binding of eGFP-WNT-3A at FZD8-CD86 and FZD8
(data also present in Figure 2B) was determined by the detection of NanoBiT/BRET in transiently overexpressing living HEK293A cells following
240 min incubation. Data points are presented as means ± SEM from n = 3−4 individual experiments. eGFP-WNT-3A batch 1 was used in the
experiments. Linear scale data are fitted to a one-site specific binding model. Logarithmic-scale data are fitted to a normalized three- or four-
parameter model. The right plot in every panel shows data normalized between 0% (BRETmin) and 100% (BRETmax) for each studied construct.
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expression levels between FZD-CD86 and wild-type (WT)
FZDs (Figure 4B).
In the NanoBiT/BRET binding experiments with the FZD4-
CD86 chimera, we could detect a concentration-dependent
increase in the BRET signal indicative of eGFP-WNT-3A
binding. Interestingly, eGFP-WNT-3A interacted with FZD4-
CD86 with a visibly lower affinity (higher Kd) and a visibly
lower maximal BRET (at the fixed concentrations used) than
for an intact FZD4 protein (FZD4-CD86 Kd ± SEM (nM) =
141.9 ± 181.5, P = 0.0991; BRETmax ± SEM = 0.019 ± 0.001
vs FZD4 BRETmax ± SEM = 0.030 ± 0.004, P = 0.0622; Figure
4C). In order to emphasize differences in Kd for the tested
receptors, the data were also normalized and are presented in a
semilogarithmic presentation in Figure 4C (FZD4-CD86 pKd
± SEM = 8.19 ± 0.04 vs FZD4 pKd ± SEM = 8.31 ± 0.05, P =
0.0331). Importantly, differences in BRETmax for FZD4-CD86
and FZD4 cannot arise from differences in surface expression
levels, as both studied receptors are similarly expressed (P =
0.3324).
Next, we performed a similar analysis for a FZD8-CD86
chimera. eGFP-WNT-3A binding to the chimera FZD8-CD86
compared to FZD8 at similar levels of receptor surface
expressions (P = 0.8340; Figure 4B) did not differ in affinity
in the analysis of non-normalized data (FZD8-CD86 Kd ±
SEM (nM) = 22.9 ± 10.6, P = 0.6668; Figure 4D), but the
difference reached statistical significance when comparing the
normalized values (P = 0.0390; Figure 4D). Furthermore, the
NanoBiT/BRET signal increased significantly when the FZD8
core was replaced by CD86. The NanoBiT/BRET signal
(BRETmax) was in fact comparable to other WNT-3A-binding
competent FZDs (FZD8-CD86 BRETmax ± SEM = 0.056 ±
0.006 vs FZD8 BRETmax ± SEM = 0.003 ± 0.0003, P = 0.0002;
Figure 4D and Figure 2). Intriguingly, these findings are the
opposite of what we observe for FZD4, where replacing the
receptor core with CD86 visibly reduced maximal BRET
(Figure 4C). The efficiency of resonance energy transfer
depends on both orientation and distance between BRET
donor and BRET acceptor.53 Thus, in the NanoBiT/BRET
binding setup, the differences in BRETmax can be interpreted as
distinct ligand−receptor conformations. This further suggests
that the cores of FZD4 and FZD8 can differently contribute to
WNT-FZD binding.
In addition to the FZD-CD86 chimeras detailed above, we
also generated FZD-FZD chimeras. Specifically, we con-
structed FZD4-FZD6, FZD4-FZD8, FZD5-FZD6, FZD5-FZD7,
and FZD6-FZD4 chimeric proteins (Figure S4B). In this
manner, we have used at least one FZD paralogue from every
FZD homology cluster. The transmembrane cores of FZD6
and FZD8 were selected to test whether they negatively affect
eGFP-WNT-3A binding to the CRD of FZD4 and FZD5. On
the other hand, the FZD7 core was chosen to assess if it
positively modulates ligand binding to the CRD of FZD5. The
rationale for this selection was based on the very weak
NanoBiT/BRET signal seen for eGFP-WNT-3A binding to
FZD6 and FZD8, and strong NanoBiT/BRET signal of eGFP-
WNT- 3A/FZD7 association in the two assay paradigms
described in this study (Figure 1B and Figure 2B). Addition-
ally, the FZD6 core was replaced with the FZD4 core to assess
whether eGFP-WNT-3A binding to FZD6 CRD would
increase upon insertion of a core from an eGFP-WNT-3A
binding-competent FZD paralogue (Figure 1B and Figure 2B).
We validated the chimeras with regard to their proper
membrane trafficking upon transient overexpression in
HEK293A cells and detected that the FZD-FZD chimera
proteins are relatively poorly expressed on the cell surface
compared to WT receptors (Figure S4C). Binding affinities of
fluorescent propranolol to HiBiT-tagged β2-adrenergic re-
ceptors vary depending on the protein expression levels, with
higher expression levels generally resulting in slightly elevated
Kd values (lower affinity).
32 Furthermore, binding affinities of
DKK1-eGFP proteins to the WNT coreceptor LRP6-mCherry
measured by dual-color axial line-scanning FCS (axial lsFCS)
were higher for lower, more physiologically relevant receptor
expression levels.54 Our data for transient overexpression of
FZD4 in HEK293A cells mostly support these notions, with
some exceptions (Figure S4D). Overall, it needs to be
emphasized that although the Kd is a thermodynamic
parameter that should be constant for various expression
levels, differences in the cellular context may lead to different
functionalities of overexpressed receptors present on the cell
surface. This in turn can affect the comparative analysis and
interpretation of real-time ligand binding data.54 However,
provided the availability of cell surface expression data in the
experimental paradigm of the NanoBiT/BRET binding assay,
we shed light on a potential role of the receptor core for WNT-
CRD binding. Focusing on the FZD4 chimeras, eGFP-WNT-
3A bound with a significantly higher affinity (lower Kd) to the
FZD4-FZD6 and the FZD4-FZD8 chimeras compared to full-
length FZD4 (FZD4-FZD6 Kd ± SEM (nM) = 3.5 ± 1.8, P =
0.0255; FZD4-FZD8 Kd ± SEM (nM) = 2.9 ± 1.3, P = 0.0371;
Figure S4E). Interestingly, BRETmax values were visibly or
significantly lower for both weakly expressed FZD4-FZD
chimeras than for the intact FZD4 (FZD4-FZD6 BRETmax ±
SEM = 0.021 ± 0.003, P = 0.0828; FZD4-FZD8 BRETmax ±
SEM = 0.010 ± 0.001, P = 0.0192).
Additionally, our data showed that in comparison to WT
FZD5, eGFP-WNT-3A binding to FZD5-FZD6 occurred with
only visibly higher affinity, but this difference did not reach
statistical significance (FZD5-FZD6 Kd ± SEM (nM) = 4.4 ±
1.5, P = 0.0638; Figure S4F). Next, the affinity of eGFP-WNT-
3A binding to FZD5-FZD7 was also not significantly different
compared with WT FZD5 (FZD5-FZD7 Kd ± SEM (nM) = 5.0
± 2.4, P = 0.2622; Figure S4F). Moreover, the differences in
BRETmax did not reach statistical significance (FZD5-FZD6
BRETmax ± SEM = 0.080 ± 0.014, P = 0.1715; FZD5-FZD7
BRETmax ± SEM = 0.098 ± 0.026, P = 0.2046; FZD5 BRETmax
± SEM = 0.051 ± 0.009).
In addition, our data indicated that eGFP-WNT-3A bound
to FZD6-FZD4 with the same affinity (FZD6-FZD4 Kd ± SEM
(nM) = 5.8 ± 3.4, P = 0.9695; Figure S4G) as to FZD6 but
with a significant, over 10-fold increase in the maximal BRET
signal (FZD6-FZD4 BRETmax ± SEM = 0.030 ± 0.006 vs FZD6
BRETmax ± SEM = 0.002 ± 0.001, P = 0.056) arguing that the
FZD6CRD can efficiently bind eGFP-WNT-3A in the context
of a different receptor core. As mentioned before, it needs to
be emphasized that receptor expression levels can affect
ligand−receptor interaction. Along these lines, in classical
BRET titration experiments, increasing BRET donor amounts
(by increasing plasmid DNA amounts) with constant BRET
acceptor levels (unchanged plasmid DNA amounts) leads to a
decrease in BRETmax signal for specific donor−acceptor
interactions.55 In contrast, no such relationship was found in
our FZD-CD86 and FZD-FZD NanoBiT/BRET binding
experiments, further supporting the notion that the FZD
core has a differential role in WNT binding depending on the
FZD paralogue.
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Here, we have used the NanoBiT/BRET system to analyze
the contribution of the FZD seven-transmembrane-spanning
core to eGFP-WNT-3A binding to the CRD. We show that
swapping the receptor core can have a substantial effect on the
affinity or maximal BRET of eGFP-WNT-3A binding in the
NanoBiT/BRET read-out. Our data, particularly from the
FZD-CD86 experiments, argue that the seven-transmembrane-
spanning core contributes to ligand binding for the tested
FZDs, even though the details on the molecular level remain
obscure.
This study adds substantial methodological advance to the
pharmacological toolbox suitable for the study of the class F
GPCRs and their coreceptors.28,54,56 We have demonstrated
the vast potential of employing fluorescent WNTs and the
NanoBiT/BRET binding technique for the pharmacological
quantification of WNT-FZD interactions in live HEK293A
cells despite the limitations that come with the low
concentration of the tracer WNT in the conditioned medium
preparation. The broader analysis of the selectivity of ligand−
receptor interactions, WNT binding in the presence or absence
of either FZD coreceptors, FZD-binding intracellular trans-
ducer proteins and at different FZD expression levels, can now
be further investigated to understand the pluridimensionality
of WNT-FZD system in a more physiologically relevant cell
system.
■ EXPERIMENTAL SECTION
Cell Culture and Ligands. HEK293A cells (ATCC),
HEK293F (Thermo Fisher Scientific, Waltham, MA, USA),
HEK293T (DSMZ ACC-635), and ΔFZD1−10 HEK293T
cells25 were cultured in DMEM supplemented with 10% FBS,
1% penicillin/streptomycin, and 1% L-glutamine (all from
Thermo Fisher Scientific, Waltham, MA, USA) in a humidified
CO2 incubator at 37 °C. All cell culture plastics were from
Sarstedt (Nümbrecht, Germany), unless otherwise specified.
The absence of mycoplasma contamination was routinely
confirmed by PCR using 5′-GGCGAATGGGTGAGTAACA-
CG-3′ and 5′-CGGATAACGCTTGCGACTATG-3′ primers
detecting 16 S rRNA of mycoplasma in the media after 2−3
days of cell exposure. Untagged human WNT-3A, human/
mouse WNT-5A, human WNT-5B, human WNT-10B, human
WNT-11, and human WNT-16B were all from RnD Systems/
Biotechne (#5036-WN, #645-WN, #7347-WN, #7196-WN,
#6179-WN, and #7790-WN, Minneapolis, MI, USA). WNTs
were dissolved at 100 μg/mL in filter-sterilized 0.1% BSA/PBS
and stored at 4 °C. Molecular weights of the WNTs were as
per supplier’s datasheets. Porcupine inhibitor C59 was from
Abcam (#ab142216, Cambridge, UK).57 C59 was dissolved in
DMSO at 5 mM and stored at −20 °C. The serial dilutions of
WNTs were prepared in the protein-low binding tubes
(Eppendorf, Hamburg, Germany).
Preparation of eGFP-WNT-3A CM. HEK293F suspen-
sion cells growing in serum-free Expi293 expression medium
(60 mL, 2.5 × 106 cells/mL) were cotransfected with 10 μg of
either pCS2+-WNT-3A or pCS2+-eGFP-WNT- 3A together with
50 μg of pCMV-His-Afamin plasmid using ScreenFect UP-293
(ScreenFect GmbH, Eggenstein-Leopoldshafen, Germany)
according to the manufacturer’s instructions. The correspond-
ing control CM was generated from cells transfected with
pCS2+ plasmid.
Cells were first cleared from the HEK293F CM by
centrifugation at 260 g (1200 rpm) for 10 min and then at
2800 g (4000 rpm) for 30 min to remove any remaining
cellular debris and insoluble material. This “raw” CM then was
concentrated 5-fold using Vivaspin turbo 15 centrifugal
concentrators (30,000-molecular-weight-cutoff, Satorius AG,
Göttingen, Germany) and exchanged to the desired cell culture
medium using Sephadex G-25 PD10 desalting columns (GE
Healthcare Bio-Science, Freiburg, Germany). The final
concentration and integrity of eGFP-WNT-3A in the CM
samples were determined using ELISA (GFP ELISA kit,
#ab171581, Abcam) and SDS-PAGE/Western Blot analysis,
respectively. Two eGFP-WNT-3A batches (eGFP-WNT-3A
batch 1 final concentration: 16.7 nM; eGFP-WNT-3A batch 2
final concentration: 16.2 nM) were used in this study. Current
WNT purification methods allow only limited WNT
concentration to be obtained from CM.58 For validation of
the eGFP-WNT-3A batches, please see Figure S5.
Plasmids. Generation of HiBiT-FZD4, HiBiT-FZD6, and
Nluc-FZD4 has been described previously.
28 Gibson cloning
was used to generate other HiBiT-tagged receptor constructs
using HiBiT-tagged backbone from HiBiT-FZD4 containing a
5-HT3A signal sequence. To generate chimeras, the N-terminal
domains (NTD; CRD with a linker region) and the
transmembrane cores were defined according to Frizzled
structures predicted on GPCRdb (http://www.gpcrdb.org),
and the constructs were generated with Gibson cloning. Nluc-
CD86 used to generate FZD-CD86 chimeras was from Martin
J. Lohse (Max-Delbrueck Center for Molecular Medicine,
Berlin, Germany). Frizzled and CD86 signal peptides were
defined with SignalIP-5.0 Server (http://www.cbs.dtu.dk/
services/SignalP/). The constructs were validated by sequenc-
ing (Eurofins GATC, Konstanz, Germany). The details of the
constructs used in this study are presented in Figure S1A,B and
Figure S4A.
NanoBiT/BRET Binding. HEK293A cells were transiently
transfected in suspension using Lipofectamine 2000 (Thermo
Fisher Scientific, Waltham, MA, USA). A total of 4 × 105 cells
were transfected in 1 mL with 1000 ng of HiBiT-tagged FZDs
or 10 ng of Nluc-FZD4 plasmid DNA. The cells (50 μL) were
seeded onto a poly(D-lysine)-coated black 96-well cell culture
plate with a solid flat bottom (Greiner BioOne). Next, 50 μL
of complete DMEM medium was added to each well. Forty-
eight hours post-transfection, the cells were washed once with
200 μL of Hanks’ balanced salt solution (HBSS; HyClone). In
the kinetic binding experiments, the cells were preincubated
with 50 μL of a mix of Nluc substrate vivazine (1:50 dilution;
#N2581, Promega, Fitchburg, WI, USA) and LgBiT (1:100
dilution; #N2421, Promega, Fitchburg, WI, USA) in a
complete, nonphenol red DMEM (HyClone) supplemented
with 10 mm HEPES for 1 h at 37 °C without CO2.
Subsequently, 50 μL of eGFP-WNT-3A conditioned medium
or control medium supplemented with 5% FBS and 10 mm
HEPES was added, and the BRET signal was measured every
90 s for 240 min at 37 °C (161 measurements, no CO2). In the
saturation-binding experiments, the cells were incubated with
different concentrations of eGFP-WNT-3A conditioned
medium (90 μL) supplemented with 5% FBS and 10 mm
HEPES for 240 min at 37 °C with no CO2. In the competition
binding experiments, the cells were preincubated for 30 min at
37 °C with 80 μL of unlabeled WNT proteins at 37 °C with no
CO2. Subsequently, 10 μL of eGFP-WNT-3A at a concen-
tration of 3.6 nM (final concentration of 0.4 nM) were added,
and the cells were incubated for further 240 min at 37 °C with
no CO2. Next, for saturation and competition binding
experiments, 10 μL of a mix of furimazine (1:10 dilution;
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#N2421, Promega, Fitchburg, WI, USA) and LgBiT (1:20
dilution; #N2421, Promega, Fitchburg, WI, USA) was added.
For saturation binding experiments with Nluc-FZD4 furima-
zine was used at 1:1000 final dilution (#N1572, Promega,
Fitchburg, WI, USA) and no LgBiT was added. The cells were
incubated for another 10 min at 37 °C with no CO2 before the
BRET measurements. The BRET ratio was determined as the
ratio of light emitted by eGFP (energy acceptor) and light
emitted by HiBiT-FZD1−10 or Nluc-FZD4 (energy donors).
The net BRET ratio was calculated as the difference in BRET
ratio between cells treated with eGFP-WNT-3A, and cells
treated with vehicle. ΔBRET ratio in the competition binding
experiment was calculated as the difference in BRET ratio of
cells treated with vehicle (eGFP-WNT-3A only wells, no
ΔBRET) and cells treated with WNTs. The BRET acceptor
(bandpass filter, 535−30 nm) and BRET donor (bandpass
filter, 475−30 nm) emission signals were measured using a
CLARIOstar microplate reader (BMG, Ortenberg, Germany).
Cell surface expression of HiBiT-tagged FZDs and total
expression of Nluc-FZD4 was assessed by measuring
luminescence of vehicle-treated wells (no BRET acceptor) in
the NanoBiT/BRET or NanoBRET binding assays, respec-
tively. eGFP fluorescence was measured prior to reading BRET
(excitation, 470−15 nm; emission, 515−20 nm).
TOPFlash Reporter Gene Assay. ΔFZD1−10 HEK 293T
cells were transfected in suspension (4 × 105 cells were
transfected in 1 mL) with 700 ng of HiBiT-tagged receptor,
250 ng M50 Super 8× TOPFlash (#12456; Addgene,
Watertown, MA, USA), and 50 ng pRL-TK Luc (#E2241,
Promega, Fitchurg, WI, USA) and seeded (50 μL) onto a
poly(D-lysine)-coated white 96-well cell culture plate with a
solid flat bottom (Greiner BioOne). Next, 50 μL of complete
DMEM medium was added to each well. Twenty-four hours
after transfection, the medium was changed to starvation
medium (DMEM without FBS) containing either 8.0 nM (300
ng/mL) WNT-3A or vehicle, and 10 nM C59. Twenty-four
hours after stimulation, cells were lysed gently shaking with 20
μL 1× Passive Lysis Buffer (#E1910; Promega, Fitchurg, WI,
USA) for 15 min. Subsequently, 20 μL of LAR II (Promega,
E1910) was added to all wells after which luminescence (580−
80 nm) was read, and then 20 μL of Stop & Glo (Promega,
E1910) was added to all wells after which luminescence (480−
80 nm) was read again with a CLARIOstar microplate reader
(BMG, Ortenberg, Germany).
Data Analysis and Statistics. All data were analyzed in
GraphPad Prism 8 (San Diego, CA, USA) using built-in
equations. All data presented in this study come from n
individual experiments (at least three biological replicates)
with each individual experiment performed typically in
duplicates (technical replicates) for each tested concentra-
tion/condition. Data points on the binding curves represent
mean ± SEM. Saturation binding curves were fit using one-
site-specific or total and nonspecific saturation nonlinear
regression models (linear scale for eGFP-WNT-3A concen-
trations) or normalized three-parameter or normalized four-
parameter nonlinear regression models (logarithmic scale for
eGFP-WNT-3A concentrations with normalized net BRET
ratio). The fitting models were selected based on an extra-sum-
of-squares F-test (P < 0.05). Kinetic binding data were
analyzed using the association model with two or more hot
ligand concentrations. Binding affinity values (Kd) are
presented as a best-fit Kd with SEM. Kd values were compared
using an extra-sum-of-squares F-test (P < 0.05). Competition
binding curves were analyzed using a three- or four-parameter
nonlinear regression model to obtain equilibrium dissociation
constant values pKi with SEM of unlabeled ligands as per the
Cheng−Prusoff equation.59 Minimal BRET (BRETmin) and
maximal BRET (BRETmax) were defined as the lowest and
highest measured net BRET ratios, respectively. BRETmax
values were compared using unpaired t-test. TOPFlash and
cell surface expression data are presented as mean ± SEM.
TOPFlash and cell surface expression data were analyzed for
differences with Brown−Forsythe and Welch one-way analysis
of variance (ANOVA); ** P ≤ 0.01, * P ≤ 0.05.
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